Phathom Pharmaceuticals, Inc. (PHAT) Minute Stock Prediction

About:

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

25

Address:

Phathom Pharmaceuticals, Inc. 100 Campus Drive Suite 102 Florham Park NJ 07932 United States

Website:

http://www.phathompharma.com

Phone:

877-742-8466